Compare PCRX & IBTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PCRX | IBTA |
|---|---|---|
| Founded | 2006 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 855.3M |
| IPO Year | 2010 | 2024 |
| Metric | PCRX | IBTA |
|---|---|---|
| Price | $25.10 | $35.31 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 7 |
| Target Price | ★ $30.25 | $28.50 |
| AVG Volume (30 Days) | ★ 398.4K | 150.0K |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 107.44 | N/A |
| EPS | ★ 0.16 | 0.12 |
| Revenue | ★ $541,533,000.00 | $342,389,000.00 |
| Revenue This Year | $6.78 | $2.02 |
| Revenue Next Year | $8.54 | $8.96 |
| P/E Ratio | ★ $158.81 | $297.92 |
| Revenue Growth | ★ 26.04 | N/A |
| 52 Week Low | $18.80 | $19.10 |
| 52 Week High | $27.64 | $56.60 |
| Indicator | PCRX | IBTA |
|---|---|---|
| Relative Strength Index (RSI) | 58.93 | 70.54 |
| Support Level | $20.56 | $21.65 |
| Resistance Level | $25.23 | $36.45 |
| Average True Range (ATR) | 0.88 | 1.12 |
| MACD | 0.09 | -0.20 |
| Stochastic Oscillator | 65.79 | 81.27 |
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
Ibotta Inc operates a digital promotions platform, the Ibotta Performance Network (IPN), which connects consumer packaged goods (CPG) brands with consumers through a network of publishers. It sources digital offers from clients and distributes them via its technology platform, earning revenue when promotions result in consumer transactions. The platform supports offers across grocery and general merchandise categories, including toys, clothing, beauty, electronics, pet, and home products. The majority of its revenues is derived from the fees charged to clients when consumers redeem offers on the IPN by purchasing promoted products.